From Albert Hofmann to 4-Pro-MET: History of Tryptamine Research

Eight decades separate Albert Hofmann's accidental discovery of LSD's effects in 1943 from 4-Pro-MET's arrival in 2025. That's a long arc. Groundbreaking discoveries, decades of prohibition, then a clinical renaissance that's still accelerating. You can't grasp where today's research chemicals fit in psychedelic science without knowing this history.

Albert Hofmann synthesized LSD (lysergic acid diethylamide) at Sandoz Laboratories in Basel, Switzerland in 1938. Five years later came the accident that changed everything. On April 19, 1943 – now commemorated as "Bicycle Day" – Hofmann absorbed a small quantity through his skin and experienced altered perception during his ride home. LSD is a lysergamide, not a tryptamine. But Hofmann's discovery cracked open the door to systematic psychedelic research.

Tryptamines came next. In 1958, Hofmann synthesized psilocybin and psilocin from Psilocybe mexicana mushrooms. By 1960, he'd determined their chemical structures and developed synthetic production methods. These discoveries put 4-substituted tryptamines on the map alongside lysergamides and phenethylamines. And the research boom that followed was staggering: between 1950 and 1970, approximately 1,000 scientific papers were published on psychedelic tryptamines, and an estimated 40,000 patients received psilocybin or LSD in therapeutic settings.

The US Controlled Substances Act of 1970 classified psilocybin and psilocin as Schedule I, halting most legitimate research for decades. Similar legislation followed globally. During this period, Alexander Shulgin – a chemist with a DEA Schedule I research license – became the most prolific psychedelic researcher in history, personally synthesizing and bioassaying hundreds of novel compounds.

Shulgin's 1997 book TiHKAL (Tryptamines I Have Known And Loved) documented 55 tryptamine compounds, including entry #21: 4-HO-MET (metocin). His notes describe it at 10-20 mg oral: "Qualitatively a lot like psilocin. I started within the first half-hour, and at the max, I felt the same alteration of color and form." 4-Pro-MET itself is NOT described in TiHKAL – it's a more recent creation that applies the established prodrug ester strategy to Shulgin's documented compound.

The modern psychedelic renaissance began in 2006 when Roland Griffiths' team at Johns Hopkins published their landmark psilocybin study – demonstrating its ability to occasion mystical-type experiences with lasting positive effects. Clinical trials followed fast: by 2026, over 15 Phase II/III trials are active or completed for psilocybin alone, targeting treatment-resistant depression, PTSD, alcohol use disorder, and end-of-life anxiety.

The research chemical market expanded in parallel. 4-HO-MET appeared as a designer substance around 2008, 4-AcO-MET and 4-AcO-DMT gained popularity through the mid-2010s, and 4-Pro-MET emerged in August/September 2025 as the latest iteration of the 4-substituted tryptamine prodrug strategy. Each compound applies Shulgin's foundational chemistry to generate legal variants with predictable pharmacological profiles.